Why the study?
What is the frequency and what are the risk factors of neuroleptic malignant syndrome in psychiatric inpatients treated with neuroleptic agents?
What is the frequency and what are the risk factors of neuroleptic malignant syndrome in psychiatric inpatients treated with neuroleptic agents?
The frequency of neuroleptic malignant syndrome in a large Russian psychiatric hospital was very low (0.02%), with young age identified as a significant risk factor.
Answers are grounded in this paper and cite their sources.
Low NMS frequency with notable mortality warrants vigilance in young inpatients; leaves open causal role of age pending prospective validation.
A ten-year prospective survey of neuroleptic malignant syndrome (NMS) was performed in a major psychiatric hospital (1,510 beds) in Moscow. All inpatients who developed a persistent and severe extrapyramidal rigidity accompanied by fever after exposure to neuroleptic medication were screened for NMS. The diagnosis of NMS was established according to Levenson's criteria and at a later stage all NMS cases were reevaluated using the DSM-IV research criteria. Data on age, gender and psychiatric diagnoses were analyzed. Of the 78,708 inpatients treated with neuroleptic agents, 19 separate patients had an episode of NMS, for a frequency of 0.02%. Mortality rate was 10.5% (2/19 patients). Of the three potential risk factors studied, only young age (</= 25 years) was significantly associated with an increased frequency of NMS (P < 0. 01). The low rate of NMS found here compared to studies in other countries may be due to the stringent demands for NMS diagnosis. More large-scale prospective studies including detailed clinical and laboratory data are needed to clarify these differences and their impact on the prevalence and risk factors of NMS.
No takes yet. Share an insight, caveat, or question.
Спивак et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: